Sex difference in progression of adriamycin-induced nephropathy in rats.
To clarify the pathogenesis of focal-segmental glomerulosclerosis, we investigated the sex-related difference and the effect of castration in Adriamycin (ADR) induced nephropathy of Sprague-Dawley rats. At 5 weeks of age, group 1 female and group 2 male rats were sham operated, and group 3 male rats were castrated. ADR 2 mg/kg was intravenously administered to all rats at 8 weeks of age twice at a 20-day interval. Body weight, blood pressure, urinary protein, and serum constituents were investigated every 4 weeks, 4-20 weeks after the second ADR injection. Each group was studied morphologically 12 and 20 weeks after the second ADR injection. ADR induced massive proteinuria in male rats, whereas it induced significantly lower proteinuria in female rats, and castration significantly reduced proteinuria of male rats to an extent equal to the levels seen in female rats. Control male rats had significantly lower serum albumin levels and a significantly greater impairment of renal function (blood urea nitrogen and creatinine levels) than the female rats or the castrated male rats at 20 weeks. The glomerulosclerosis index was significantly higher in control male rats than in female rats, and castration attenuated glomerular injury of male rats to an extent close to the levels seen in female rats, though there was a significant difference in the glomerulosclerosis index between female rats and castrated male rats. The three groups did not differ in blood pressure and plasma somatomedin C and serum growth hormone levels, whereas the plasma testosterone levels were decreased to undetectable in female and castrated male rats, resulting in a reduction of sex-related low molecular weight protein in urine. These observations suggest that sex hormones such as testosterone and estrogen and/or sex-related low molecular weight protein regulated by testosterone and estrogen may play a contributory role in sex differences in the progression of glomerulosclerosis in ADR-treated rats.
Sakemi
T
T
Department of Internal Medicine, Saga Medical School, Japan.
Ohtsuka
N
N
Tomiyoshi
Y
Y
Morito
F
F
D000818:Animals; D000903:Antibiotics, Antineoplastic; D001794:Blood Pressure; D002369:Castration; D004195:Disease Models, Animal; D018450:Disease Progression; D004317:Doxorubicin; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D013006:Growth Hormone / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007668:Kidney / Q000473:pathology; D008297:Male; D009929:Organ Size; D011507:Proteinuria; D051381:Rats; D017207:Rats, Sprague-Dawley; D012709:Serum Albumin / Q000032:analysis; D012737:Sex Factors; D013739:Testosterone / Q000097:blood
D000903:Antibiotics, Antineoplastic; D012709:Serum Albumin; D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D004317:Doxorubicin; D013006:Growth Hormone